Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Nihon Chouzai Launches Drug Information Service with Standard Formulary Including Few New Meds
July 27, 2020
- Chiome to Launch First-in-Human Trial for Anti-DLK-1 Antibody
July 22, 2020
- Shonan iPark’s VC Consortium Now Up and Running
July 22, 2020
- 9-Valent HPV Vaccine Hits Finish Line, but Japan Launch Schedule Uncertain with High Global Demand
July 22, 2020
- Mochida, Shimane Univ. Start Collaborative Research on New Treatment for Joint Disease
July 22, 2020
- Daiichi Sankyo’s Prasugrel Hits Primary Goal in Japan PIII for Thrombotic Stroke, Filing for Label Expansion Planned in 2021
July 22, 2020
- MSD Launches Injectable Version of Deep Mycosis Drug Noxafil
July 22, 2020
- Japan Approves MSD’s 9-Valent HPV Vaccine 5 Years after Filing
July 21, 2020
- AstraZeneca Aims to Deliver100 Million Doses of Coronavirus Vaccine to Japan: CEO
July 21, 2020
- National CV Center Spin-Off Developing Oligonucleotide Therapy for Dyslipidemia, Eyes 1st Trial in FY2022
July 20, 2020
- Mitsubishi Tanabe Earns Indonesian OK for ALS Med
July 17, 2020
- Kyowa Pharma Expanding Focus Beyond Drugs, Eyes New Diagnostic/Treatment Options in CNS
July 17, 2020
- With New Chief at Helm, Mitsubishi Tanabe Looks to Boost Presence in Overseas Markets
July 16, 2020
- Medicago Begins PI Trial of COVID-19 Vaccine in Canada
July 16, 2020
- SanBio to Focus on Cell Therapy SB623 for Brain Injury, Stroke, Seeking Licensees for Other Indications
July 16, 2020
- Astellas to Transfer Antipsychotic Dogmatyl to Nichi-Iko
July 15, 2020
- Eisai Starts PIII Preclinical Alzheimer’s Study for BAN2401
July 15, 2020
- Shionogi, Ping An to Set Up JV in August, Make It a Hub for China/Asia Biz
July 14, 2020
- Nichi-Iko Execs Face Pay Cuts over Massive Recalls
July 14, 2020
- Keio Prof. Kenya Honda Becomes Scientific Advisor for 4BIO
July 14, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…